A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes

In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.

Authors

Institutions

Publication Details

Journal
Diabetes Care
Published
2024-12-06
DOI
https://doi.org/10.2337/dc24-1832
Citations
20
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
7.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes

Andrea D. Coviello, Martin Chase Marak, Jamie Hyatt, Carol J. Levy et al.
20 citations
Diabetes Care
Diabetes Management and Research
7.15
article

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes

Andrea D. Coviello, Martin Chase Marak, Jamie Hyatt, Carol J. Levy, Thomas Blevins, Bruce W. Bode, David Pickering, Karla Fulghum, Jonathan G. Ownby, Philip Raskin, Halis Kaan Aktürk, Shilton Dhaver, Alexander Kass, Jesica D. Baran, E E Mason, Anuj Bhargava, Irl B. Hirsch, Tina Copple, Corey Reid, Richard M. Bergenstal, Grenye O’Malley, Shafaq Rizvi, John B. Buse, Joseph H. Johnson, Chris McCarthy, Kristin Castorino, Astrid Atakov-Castillo, Donna Desjardins, Adriana Ruiz, Camilla Levister, Kevin B. Kaiserman, Mark S. Kipnes, Christopher Jacobson, Devin Steenkamp, E. N. Dolzhenko, Laura Young, Adham Mottalib, Valerie Espinosa, Terri Ryan, Katrina J. Ruedy, Tahereh Ghorbani, Yogish C. Kudva, Jamie Diner, Howard Wolpert, Jelena Kravarusic, Jesica Baran, Anastasios Manessis, Olivia Johnson, Kevin Codorniz, Grazia Aleppo, Sarah Frey, Ashley Thorsell, Loida Nguyen, Zehra Haider, Maria Patruno, Johanna Ulloa, Ruth S. Weinstock, Roy W. Beck, Andrew Ahmann, Klara R. Klein, Christie Beatson, Patali Mandava, Suzan Bzdick, Rosanna Holod, Amna Salhin, Osama Hamdy, Tareq Salah, Paige Miller, Marwa Al Badri, Jennifer Pleitez, Baomei Shao, Scott Lee, Ravinder Jeet Kaur, Christine Burke, Peter Calhoun, Sue A. Brown, Keta Pandit, Ana Stewart, Maggie Shuirman, Nnenna Mba-Oduwusi, Ashleigh Fults, Denisa Tamarez, Christine Langel, Daine Livingood, Evelyn Fronczyk, Lorcan McKillop, Olivia Watt, Maritza Martinez-Arredondo, Joey Sylvan, Lynn Badgett, Amanda Maxson, Brittney Migliozzi, Dana Cruse, Jennifer Perez, A. Bohr, Kasey Coyne, Brandon Cobb, Cassandra Donahue, Asya Sullivan, Rosa Pritchard, Chloe Armstrong, Stefanie Herrmann, Sarah Borgman, Deanna Gabrielson, Luis Casaubon, Aslihan Ipek, Nashia Stephens, Stephanie Beltran, Cristina Haight, Corey Kurek, Christian Cordero, Quang T. Nguyen, Lin Jordan, Shannon Bauman
article en
20 citations

Abstract

In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.

Diabetes CareVol. 48(3)
Boston University (US), Northwestern University (US), University of North Carolina at Chapel Hill (US), Boston Medical Center (US), Midwestern University (US), Joslin Diabetes Center (US), University of Washington (US), SUNY Upstate Medical University (US), Loma Linda University (US), West Virginia University at Parkersburg (US), Sansum Diabetes Research Institute (US), Atlanta Diabetes Associates (US), Diabetes & Glandular Disease Clinic (US), Mayo Clinic in Arizona (US), Texas Diabetes & Endocrinology (US), Jaeb Center for Health Research (US), Iowa Diabetes and Endocrinology Research Center (US), The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Northwestern University, Vertex Pharmaceuticals, Ionis Pharmaceuticals, Bigfoot Biomedical, Insulet Corporation, MannKind Corporation, Dexcom, Kowa Company, Jaeb Center for Health Research, Tandem Diabetes Care, Moderna, Novo Nordisk, Abbott Diabetes Care, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 2%
Diabetes Management and Research
7.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.